Customer advocacy program to provide media promotion of CardioComm Solutions Case Study
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed SunGard Availability Services (Canada) Ltd, a subsidiary of SunGard Data Systems Inc. (“SunGard’), will be promoting CardioComm Solutions in a case study related to the Company’s use of their cloud-based systems infrastructure as the platform for the HeartCheckTM-based SMART Monitoring service.
“Since the launch of the SMART Monitoring service in September 2012, CardioComm Solutions has proved to be a valued SunGard customer with a great story to tell,” said Lillian Kann, Sr. Programs Manager, Customer Marketing for SunGard Availability Services. “It is a privilege to be supporting them in the expansion of the use of their innovative and disruptive ECG service products through HeartCheckTM PEN.”
The recently completed CardioComm Solutions case study will be promoted by SunGard through several channels including its corporate website, newsletter, as well as social media outlets. Participation in SunGard’s Customer Advocacy Program may also lead to further exposure among IT industry analysts and IT publications. In addition, the case study will be used by CardioComm Solutions in its marketing materials for the sale of HeartCheckTM products and SMART Monitoring services internationally.
“SunGard Availability Services brand recognition and highly available services were a natural fit as a partner with them and their HeartCheckTM PEN-based ECG SMART Monitoring solution. We are pleased to have the opportunity to partner with them and are supportive of their success and future growth plans,” said Simon Withers, Vice President of Product Development at SunGard Availability Services.
“This promotion of the SunGard case study is an external confirmation of our technical capabilities and is but one component of our Q3 and Q4 efforts to secure independent validation of our HeartCheckTM-based ECG SMART Monitoring solution. With orders under review from several regions of the world, buyers are intent to have independent confirmation of the system’s infrastructure quality and medical reliability for the services component of our business plan following the upfront hardware sales,” says Etienne Grima, Chief Executive Officer of the Company.
“With this validation of our technical capabilities, stability, scalability, medical accuracy and security of medical and personal information in place we are looking ahead to secure medical validation HeartCheckTM devices and SMART Monitoring technologies. We are on track to provide public updates to the market and our interested distributor channels, medical validation of our products when compared to traditional clinic-based ECG technologies as well as participation in large-scale peer-reviewed research,” stated Etienne Grima.
More information regarding the HeartCheckTM products and SMART Monitoring solutions is available at the Company’s web site www.theheartcheck.com.
